After this afternoon's 4.6% surge to $99.99 per share, Guardant Health might just keep moving past its target price of $99.0. With an average analyst rating of buy, and target prices from $60.0 to $120.0, the stock's next move is anyone's guess.
The stock has an average amount of shares sold short at 7.0%, and a short ratio of 3.31. The company's insiders own 4.18% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 97.0% of Guardant Health's shares being owned by this investor type.
Institutions Invested in Guardant Health
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-09-30 | Vanguard Group Inc | 9% | 11,908,829 | $1,190,763,786 |
| 2025-09-30 | Blackrock Inc. | 9% | 11,429,315 | $1,142,817,182 |
| 2025-09-30 | BAILLIE GIFFORD & CO | 4% | 5,127,692 | $512,717,912 |
| 2025-09-30 | Invesco Ltd. | 4% | 4,929,543 | $492,904,994 |
| 2025-09-30 | Capital International Investors | 4% | 4,689,241 | $468,877,197 |
| 2025-09-30 | Price (T.Rowe) Associates Inc | 3% | 4,221,637 | $422,121,474 |
| 2025-09-30 | Deep Track Capital, Lp | 3% | 4,154,086 | $415,367,050 |
| 2025-09-30 | Eventide Asset Management LLC | 3% | 3,321,338 | $332,100,579 |
| 2025-09-30 | Wellington Management Group, LLP | 3% | 3,249,085 | $324,876,002 |
| 2025-09-30 | Geode Capital Management, LLC | 2% | 2,936,656 | $293,636,227 |
Besides an analyst consensus of little upside potential, other market factors point to there being positive market sentiment on Guardant Health.
